BIAL Biotech is a center of excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster. BIAL Biotech is a wholly owned subsidiary of BIAL.
We are dedicated to innovative, research and development in the field of neurodegeneration.
Our lead program builds on the genetic association between Parkinson’s disease (PD) and the GBA1 gene. BIAL Biotech team has extensive experience in drug discovery and development, focused on genetic and neurodegenerative diseases. Our team is highly motivated to make a real difference as soon as possible for patients with severe neurodegenerative and neurodevelopmental disease.
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.